Optimi Health (TSE:OPTI) has released an update.
Optimi Health has launched OptiMed, a digital portal aimed at assisting Australian psychiatrists in prescribing psychedelic medicines such as psilocybin and MDMA. The portal, created in collaboration with Mind Medicine Australia, offers resources and training to ensure safe and effective treatment through the Authorised Prescriber Scheme. Optimi Health emphasizes its commitment to high-quality, GMP-compliant production standards for these substances, with plans to expand the portal’s access internationally in the future.
For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.
